[BMJ Publishing Group Ltd and European League Against Rheumatism Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13â16 June 2018 - ()] Saturday, 16 JUNE 2018 - SAT0293â Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
Nash, P., Coates, L.C., Kivitz, A.J., Mease, P.J., Gladman, D.D., Covarrubias-Cobos, J.A., Fleishaker, D., Wang, C., Kudlacz, E., Menon, S., Fallon, L., Hendrikx, T., Kanik, K.S.DOI:
10.1136/annrheumdis-2018-eular.3115
File:
PDF, 413 KB